Reprint

Modern Pharmaceutics for Cardiovascular Diseases

Edited by
January 2024
226 pages
  • ISBN978-3-0365-9980-9 (Hardback)
  • ISBN978-3-0365-9979-3 (PDF)

This book is a reprint of the Special Issue Modern Pharmaceutics for Cardiovascular Diseases that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

Although various non-pharmaceutical strategies addressed to the primary prevention of cardiovascular diseases such as tobacco control policies, reducing the consumption of harmful food, and increasing physical activity still represent a key strategy, often they are not sufficient. Moreover, despite the availability of a plethora of pharmaceutic approaches specifically targeting mechanisms involved in cardiovascular diseases over recent years, the burden of these pathologies has only been marginally alleviated. Therefore, new pharmaceutical and non-pharmaceutical strategies are necessary for both primary and secondary prevention to reduce the burden of cardiovascular diseases. The present reprint brings together original and review articles aiming to highlight the advances in the development of modern pharmaceutics for cardiovascular diseases in recent years.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
aspirin; coronary artery disease prevention; gastric protection; micronization; collagen cogrinding; arterial hypertension; HTN; nuclear factor erythroid factor 2-related factor 2; Nrf2; oxidative stress; antioxidant; atherosclerosis; pharmacotherapy; emergent therapeutics; natural anti-atherosclerotic products; lipids; lipoproteins; small dense LDL; cholesterol; prevention; therapy; atherosclerosis; inflammation; colchicine; NLRP3 inflammasome; coronary artery disease; acute coronary syndrome; heart failure; contractility; calcium; cardiomyocyte; myofilament; HDAC inhibitor; antifibrotic strategies; cardiac fibrosis; cardiovascular diseases; fibrosis pathways; therapeutic strategies; regenerative medicine; cell-free secretomes; paracrine factors; single-cell RNA sequencing; serine protease inhibitor; endothelial barrier; renin-angiotensin-aldosterone system; RAAS; angiotensin-converting enzyme-2; ACE2; angiotensin 1-7; Ang (1-7); COVID-19; long-term effects; heart failure; angiotensin receptor–neprilysin inhibitor; sodium-glucose co-transporter-2 inhibitors; soluble guanylate cyclase activator; cardiac myosin activation; autonomic modulation; SGLT2i; empagliflozin; heart failure; NHE1; NHE11; sodium channel